BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:From Cell Signaling to the Tumor Microenvironment\, Exploit TG
 F-β’s Role in IO to Harness a Clinically Relevant\, Safe &amp\; Efficacio
 us Therapeutics\n\nIt is clear the world of TGF-β contains vast potential
  and excitement\, in the past year alone we have seen great advances\, cl
 inical setbacks\, and novel insights into the role of TGF-β.\n\nOver the 
 last 12 months\, we have seen so many highs and lows\, including clinical
  updates from large pharma such as Novartis\, Oncotelic Therapeutics\, Sa
 nofi. It is also exciting to see emerging biotechs progressing in this ar
 ea – from Transcenta’s clearance with the FDA for Ph1 anti-PD-L1/TGFb ant
 ibody to Lassen Therapeutics uncloaking $31m for their candidate.\n\nWith
  the vast volume of candidates moving into the clinic\, it is vital for t
 his community to reconnect at the 2nd TGF-β for Immuno-Oncology Drug Deve
 lopment Summit\, the definitive industry-led meeting to harness the thera
 peutic potential of this target and supercharge pipeline progression.\n\n
 Tailored with 31+ senior leaders\, the 2022 meeting will return with a fr
 esh speaker line-up and dedicated 2 tracks content for a comprehensive gu
 ide on TGF-β in immuno-oncology. Whether you are new to this field or a s
 easoned expert\, this meeting will provide you with the must-know takeawa
 ys from biology to translational modeling\, from biomarkers to clinical t
 rial design across 3 days.\n\nWhat’s New in 2022?- Improve our core under
 standing of TGF-β function and biology- With insights from Genentech\, Le
 ucid Bio\, NIH and more\, this summit will provide a comprehensive guide 
 on the basic science of TGF-β- Better mechanistic knowledge of TGF-β regu
 lators- Leverage insights into the interplay of cells in the tumor landsc
 ape and explore the methods for targeting TGF-β with Mestag Therapeutics\
 , Takeda\, and Kalivir Immunotherapeutics- Gain novel insights into TGF-β
  and therapeutic interactions through advanced modeling- Revolutionize pr
 eclinical insights with a new TGF-β reporter mouse from Lalage Wakefield 
 and dive into current preclinical studies with Morphic and Synthis- Eleva
 te translation to avoid high toxicity profiles- Examine PK/PD modeling to
  provide insights into toxicity and avoid clinical setbacks with iOnctura
 - Layout a clear biomarker and patient selection strategy- Develop a comp
 rehensive biomarker strategy with Scholar Rock and explore the impact of 
 patient selection to drive the greatest advantages for patients- Understa
 nd past journeys and clinical setbacks to drive future success- Explore t
 he lessons learned from Novartis’ journey with TGF-β and understand the h
 istory of TGF-β in oncology – including lessons from the clinical experie
 nce of galunisertib\n
DTEND:20220127T170000
DTSTAMP:20260512T230902Z
DTSTART:20220125T090000
LOCATION:Online\, \,
SEQUENCE:0
SUMMARY:From Cell Signaling to the Tumor Microenvironment\, Exploit TGF-β’
 s Role in IO to Harness a Clinically Relevant\, Safe &amp\; Efficacious T
 herapeutics...
UID:0f2350f2-6cbe-45ea-ad36-3bc7173cfbe1
END:VEVENT
END:VCALENDAR